Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

NCT03644511 · clinicaltrials.gov ↗

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped The interest of potential centers is very limited.

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Regorafenib (Stivarga, BAY73-4506)
DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer